Elpiscience has partnered with Astellas Pharma through a fresh research and licensing deal to develop innovative dual-targeting macrophage engagers.

Cytokinetics Reveals Encouraging Outcomes in Key Phase 3 Study Called SEQUOIA-HCM, Evaluating Aficamten for Obstructive Hypertrophic Heart Condition.

Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.

RayzeBio's RYZ101 targets SSTR2, often overexpressed in GEP-NETs and extensive stage small cell lung cancer.

Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.

Chugai Pharma announced preclinical results for their antibody, DONQ52, published in Nature Communications.

LegoChem Biosciences announced a licensing deal with Janssen Biotech to develop and market LCB84, a Trop2-targeted antibody-drug conjugate.

Zealand Pharma has officially presented a request for drug approval to the United States' FDA for their medication glepaglutide, aiming to treat individuals with short bowel syndrome.

Senti Bio has received the green light from the FDA for SENTI-202, aimed at addressing recurring or stubborn blood cancers, such as Acute Myeloid Leukemia.

Tyra Biosciences successfully administered the inaugural dose of TYRA-200 to a patient and shared encouraging progress on their TYRA-300 development.

U.S. health authorities expedite assessment of Patritumab Deruxtecan for select cases of advanced or widespread EGFR-altered Non-Small Cell Lung Cancer after first treatments.

Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.